Hardin v. McMaster, 480 U.S. 947 (1987). · Go Syfert
Search
Hardin v. McMaster, 480 U.S. 947 (1987). Cases Citing This Book View Copy Cite
290 citation events (32 in the last 25 years) across 41 distinct courts.
Strongest positive: Boston Scientific Corp. v. Johnson & Johnson (cand, 2007-03-14)
Treatment trajectory · 1988 → 2026 · click a year to view as-of
1988 2007 2026
Top citers, strongest first. 34 distinct citers. How cited ↗
cited Cited "see" Boston Scientific Corp. v. Johnson & Johnson
N.D. Cal. · 2007 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.Cir.1986), cer t. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" Plant Genetic Systems, N v. & Biogen, Inc. v. DeKalb Genetics Corp.
D. Conn. · 2001 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies Inc., 802 F.2d 1367, 1384 (Fed.Cir.1986), cert. den’d, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987). “[T]here must be sufficient disclosure, either through illustrative examples or terminology, to teach those of ordinary skill how to make and use the invention as broadly as it is claimed.” In re Vaeck, 947 F.2d 488, 496 (Fed.Cir.1991).
cited Cited "see" CFMT, Inc. v. Steag Microtech, Inc.
D. Del. · 1998 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379 (Fed.Cir.), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" Perseptive Biosystems, Inc. v. Pharmacia Biotech, Inc.
D. Mass. · 1998 · signal: see · confidence high
See Innovative Scuba Concepts v. Feder Indus., 26 F.3d 1112, 1115 (Fed.Cir.1994) (citing Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987)); cf. LaBounty Mfg., Inc. v. U.S. Int’l Trade Comm’n, 958 F.2d 1066, 1070 (Fed.Cir.1992) (holding that claims for “inequitable conduct,” which arise when applicants or their attorneys breach their duty of candor to the patent office, must be proved by challenging party by clear and convincing evidence); see also Gregory E.
discussed Cited "see" Ferag AG v. Grapha-Holding AG
D.D.C. · 1996 · signal: see · confidence high
To be enabling under § 112, the patent specification must teach those skilled in the art how to make and use the full scope of the claimed invention without “undue experimentation.” In re Wright, 999 F.2d 1557, 1561 (Fed.Cir.1993); see Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" Paul Schendel v. Benson M. Curtis, Linda S. Park, and David J. Cosman (2×)
Fed. Cir. · 1996 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 , 231 USPQ 81, 87 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see" Ppg Industries, Inc. v. Guardian Industries Corporation
Fed. Cir. · 1996 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1385 , 231 USPQ 81, 94-95 (Fed.Cir. 1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see" Fonar Corp. v. General Electric Co.
E.D.N.Y · 1995 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376, 1379 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see" In Re Miguel F. Brana, Jose M.C. Berlanga, Marina M. Moset, Erich Schlick and Gerhard Keilhauer
Fed. Cir. · 1995 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384 , 231 USPQ 81, 94 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" In Re John B. Johenning
Fed. Cir. · 1994 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379-80 , 231 USPQ 81, 90 (Fed.Cir.1986), cert. denied, 480 U.S. 947 (1987). 11 Johenning's first point is that Saputo is non-analogous art, and thus the Board erred in its reliance on that reference to support its rejection.
cited Cited "see" Innovative Scuba Concepts, Inc. v. Feder Industries, Inc., D/B/A Scuba Manufacturing
Fed. Cir. · 1994 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 , 231 USPQ 81, 87 (Fed.Cir.1986), ce rt. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see" Schneider (Europe) AG v. SciMed Life Systems, Inc.
D. Minnesota · 1994 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987); Lindemann, 730 F.2d at 1460-61 . 281.
discussed Cited "see" Dblkm Inc. v. Resolution Trust Corporation
3rd Cir. · 1992 · signal: see · confidence high
See Windon Third Oil & Gas Drilling Partnership v. FDIC, 805 F.2d 342, 346 (10th Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1605 , 94 L.Ed.2d 791 (1987). 12 For DBLKM to prevail on its contribution claim it must establish that Capitol Federal is liable as a aider-and-abettor of the primary violation of the securities laws.
cited Cited "see" Fed. Sec. L. Rep. P 96,874 First Interstate Bank of Denver, N.A. And Jack K. Naber v. Roy I. Pring and Central Bank and Trust Company of Denver
1st Cir. · 1992 · signal: see · confidence high
See Windon Third Oil & Gas Drilling Partnership v. FDIC, 805 F.2d 342, 346 (10th Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1605 , 94 L.Ed.2d 791 (1987).
cited Cited "see" DBLKM Inc. v. Resolution Trust Corp.
10th Cir. · 1992 · signal: see · confidence high
See Windon Third Oil & Gas Drilling Partnership v. FDIC, 805 F.2d 342, 346 (10th Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1605 , 94 L.Ed.2d 791 (1987).
cited Cited "see" Pall Corp. v. Micron Separations, Inc.
D. Mass. · 1992 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379 (Fed.Cir.1986), cer t. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" Scripps Clinic & Research Foundation, Revlon, Inc., and Rorer Group Inc. v. Genentech, Inc., Defendant/cross-Appellant, and Miles, Inc., Scripps Clinic & Research Foundation and Revlon, Inc. v. Chiron Corporation
Fed. Cir. · 1991 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1369, 1379 , 231 USPQ 81, 90 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987). 92 The concealment asserted by Genentech relates to the monoclonal antibodies that bind the Factor VIII complex in the initial step of separation from plasma.
cited Cited "see" Scripps Clinic & Research Foundation v. Genentech, Inc.
Fed. Cir. · 1991 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1369, 1379 , 231 USPQ 81, 90 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see" Pharmacia, Inc. v. Frigitronics, Inc.
D. Mass. · 1989 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see" Germain v. Colorado State University (In Re Windrush Associates II)
Bankr. D. Conn. · 1989 · signal: see · confidence high
See Connecticut Performing Arts Found. v. Brown, 47 B.R. 911 (D.Conn.1985), aff'd, 801 F.2d 566 (2d Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1607 , 94 L.Ed.2d 793 (1987); WJM, Inc. v. Massachusetts Dep’t. of Pub.
discussed Cited "see" Sun Studs, Inc. v. Ata Equipment Leasing, Inc., Applied Theory, Inc. And U.S. Natural Resources, Inc., Defendants/cross-Appellants
Fed. Cir. · 1989 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 , 231 USPQ 81, 87 (Fed.Cir.1986), ce rt. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987) (discussing determination of priority of invention under § 102(g), and noting that “§ 102(g) prior art can be used for § 103”, id. at 1371 n. 1, 231 USPQ 84 n. 1).
cited Cited "see" Creative Manufacturing, Inc., Plaintiff/cross-Appellant v. Unik, Inc.
Fed. Cir. · 1989 · signal: see · confidence high
See Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1380 , 231 USPQ 81, 91 (Fed.Cir.1986), cert. denied, 480 U.S. 947 (1987).
discussed Cited "see" Spalding & Evenflo Companies, Inc. v. Acushnet Co.
D. Mass. · 1989 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1375 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987); Medtronic, Inc. v. Cardiac Pacemakers, Inc., 721 F.2d 1563, 1567 (Fed.Cir.1983); Stratoflex, Inc. v. Aeroquip Corp., 713 F.2d 1530, 1534 (Fed.Cir.1983).
cited Cited "see" Polysius Corp. v. Fuller Co.
E.D. Pa. · 1989 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384 (Fed.Cir. 1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987). b.
cited Cited "see" Scripps Clinic & Research Foundation v. Genentech, Inc.
N.D. Cal. · 1989 · signal: see · confidence high
See Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see, e.g." Omegaflex, Inc. v. Parker Hannifin Corp.
D. Mass. · 2006 · signal: see also · confidence low
Fundamentals § 20:10 (2d ed.2005); see also Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1375 (Fed.Cir.1986) (noting the presumption of patent validity pertains “to the patent statute as a whole ”) (emphasis in original), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
cited Cited "see, e.g." EI DuPont De Nemours and Co. v. Monsanto Co.
D. Del. · 1995 · signal: see, e.g. · confidence low
See, e.g., Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see, e.g." William S. Credle, Jr. And Debra Boone Overman v. Curtis J. Bond
Fed. Cir. · 1994 · signal: see also · confidence low
If the claims read in light of the specification reasonably apprise those skilled in the art of the scope of the invention, [section] 112 demands no more.” Miles Lab., Inc. v. Shandon Inc., 997 F.2d 870, 875 , 27 USPQ2d 1123, 1126 (Fed.Cir.1993), cert. denied, - U.S. -, 114 S.Ct. 943 , 127 L.Ed.2d 232 (1994); see also Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1385 , 231 USPQ 81, 94-95 (Fed.Cir.1986), ce rt. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see, e.g." In Re Robert H. Blamer
Fed. Cir. · 1993 · signal: see, e.g. · confidence low
See, e.g., Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1383 , 231 USPQ 81, 93 (Fed.Cir.1986), cert. denied, 480 U.S. 947 (1987). 3 The claimed invention as a whole in this case is a microwave popcorn bag and/or a method for making such a bag.
discussed Cited "see, e.g." Engel Industries, Inc. v. The Lockformer Company, Iowa Precision Industries, Inc. And Met-Coil Systems Corporation
Fed. Cir. · 1991 · signal: see also · confidence low
See also Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384-85 , 231 USPQ 81, 94 (Fed.Cir.1986), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987) (absence of detailed disclosure of best mode for screening or producing monoclonal antibodies, known in the art, did not constitute proof of concealment); In re Sherwood, 613 F.2d 809, 816-17 , 204 USPQ 537, 544 (CCPA 1980), cert. denied, 450 U.S. 994 , 101 S.Ct. 1694 , 68 L.Ed.2d 193 , 210 USPQ 776 (1981) (disclosure adequate where it “delineates the best mode in a manner sufficient to require only the applicati…
cited Cited "see, e.g." Amgen, Inc., Plaintiff/cross-Appellant v. Chugai Pharmaceutical Co., Ltd., and Genetics Institute, Inc.
Fed. Cir. · 1991 · signal: see, e.g. · confidence low
See e.g., Hybrtech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1376 , 231 USPQ 81, 87 (Fed.Cir.1986), cer t. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
discussed Cited "see, e.g." In Re Pieter Kramer
Fed. Cir. · 1991 · signal: see, e.g. · confidence low
See, e.g., Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1383 , 231 USPQ 81, 93 (Fed.Cir.1986), cert. denied, 480 U.S. 947 (1987). 3 The claimed invention as a whole in this case is a record carrier which employs depressions formed on a radiation-transmitting substrate as the optical structure and yet operates reflectively by employing a reflective layer on one side of the optical structure.
discussed Cited "see, e.g." Ziggity Systems, Inc. v. Val Watering Systems
E.D. Pa. · 1990 · signal: see, e.g. · confidence low
See, e.g., Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367 , 1380 n. 4 (Fed.Cir.1986) (the simultaneous development of a similar invention may or may not be indicative of obviousness depending on the surrounding circumstances and the other evidence in the case), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987); In re Merck, 800 F.2d at 1098 (holding of obviousness affirmed on the basis of the teachings of the prior art references in combination, not on the basis of the contemporaneous invention); Environmental Designs v. Union Oil Co. of Cal., 713 F.2d 693 , 698…
discussed Cited "see, e.g." General Electric Co. v. Hoechst Celanese Corp.
D. Del. · 1990 · signal: see, e.g. · confidence low
See, e.g., Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1379 (Fed.Cir.1986) (“for prior art to anticipate under § 102 it has to meet every element of the claimed invention”), cert. denied, 480 U.S. 947 , 107 S.Ct. 1606 , 94 L.Ed.2d 792 (1987).
Retrieving the full opinion text from the archive…
Hardin
v.
McMaster
No. 86-1324.
Supreme Court of the United States.
Mar 30, 1987.
480 U.S. 947
Published

C. A. 5th Cir. Certio-rari denied.